Clinical Trials Logo

Leber Congenital Amaurosis clinical trials

View clinical trials related to Leber Congenital Amaurosis.

Filter by:

NCT ID: NCT01014052 Completed - Clinical trials for RP (Retinitis Pigmentosa)

Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is: - to evaluate the safety of oral QLT091001 - to evaluate whether 7-day treatment with oral QLT091001 can improve visual function in subjects with LCA or RP due to RPE65 or LRAT mutations - to evaluate duration of visual function improvement (if observed)

NCT ID: NCT00821340 Completed - Clinical trials for Leber Congenital Amaurosis

Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations

Start date: February 1, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to examine the safety of gene therapy for Lebers Congenital Amaurosis (LCA) caused by RPE65 mutations using a recombinant adeno-associated virus serotype 2 (rAAV2) vector carrying the human RPE65 (hRPE65) gene. Recently, three independent short-term gene therapy studies in humans with LCA due to RPE65 mutations were published, suggesting that subretinal delivery of rAAV virus carrying the RPE65 gene is safe. As a secondary outcome, improvement in visual function was observed in seven of the first nine treated patients. The proposed study is a similar open label, Phase I clinical trial of uniocular subretinal rAAV2-hRPE65 administration to individuals with RPE65-associated retinal disease. Two cohorts of three subjects each and one cohort of four subjects will be included in this trial. Cohort 1 and 2 will consist of individuals 18 years of age and older and Cohorts 3 will consist of individuals 8 years of age and older. In cohort 2, a larger volume of vector will be administered. Enrollment in Cohort 3 will begin only after confirming the safety of rAAV2-hRPE65 administration in the older group of participants.

NCT ID: NCT00749957 Completed - Clinical trials for Leber Congenital Amaurosis

Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis

Start date: June 17, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of an adeno-associated virus vector expressing RPE65 in patients with Leber congenital amaurosis caused by mutations in the RPE65 gene. Funding Source - FDA OOPD

NCT ID: NCT00643747 Completed - Clinical trials for Retinal Degeneration

Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

Start date: January 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to determine whether gene therapy is safe and effective for the treatment of severe childhood blindness caused by mutations in RPE65.

NCT ID: NCT00516477 Completed - Clinical trials for Leber Congenital Amaurosis

Safety Study in Subjects With Leber Congenital Amaurosis

Start date: September 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether gene transfer will be safe and effective in the treatment of Leber Congenital Amaurosis (LCA).